The potential of spiramycin in modern gynecological practice
Apolikhina I.A., Suleimanova Zh.Zh., Teterina T.A.
Background: Empirical antibiotic therapy can be a necessary solution when rapid treatment is needed before the results of microbiological tests are available. One of these medications is spiramycin, an antibiotic of the macrolide group, which has a wide range of activity and proven effectiveness in combating a number of infectious diseases.
Objective: To analyze the efficacy and safety of spiramycin in gynecological practice.
Results: Modern antibacterial therapy presents several challenges, including the risk of increased antibiotic resistance, the likelihood of adverse reactions, and high economic costs. Spiramycin plays an important role in the treatment of gynecological infections due to its effectiveness against a variety of pathogens, including intracellular pathogens such as Chlamydia trachomatis and Toxoplasma gondii. Its ability to penetrate the placental barrier and create high tissue concentrations, as well as its relative safety for pregnant women, make this drug a preferred choice in a number of clinical situations. An important advantage of spiramycin is its low incidence of resistance, which sets it apart from other macrolides. Additionally, it has minimal effects on the microbiome and rarely causes side effects, which enhances patient compliance with treatment.
Conclusion: Spiramycin is characterized by high efficacy against a wide range of pathogens, safety and low incidence of antibiotic resistance. Nevertheless, the administration of spiramycin requires an individual approach and consideration of all risk factors and contraindications. Following the doctor’s recommendations and completing the prescribed course of treatment are essential for successfully getting rid of infectious diseases and preventing recurrences.
Authors’ contributions: Teterina T.A., Suleimanova Zh.Zh. – collecting publications, processing and analysis of materials, writing the text, translation of the articles; Apolikhina I.A. – editing the article.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Apolikhina I.A., Suleimanova Zh.Zh., Teterina T.A.
The potential of spiramycin in modern gynecological practice.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (10): 173-179 (in Russian)
https://dx.doi.org/10.18565/aig.2025.259
Keywords
spiramycin
antibiotic therapy
PID
chlamydia
toxoplasmosis
antibiotic resistance
References
- Бутранова О.И., Зырянов С.К., Абрамова А.А. Спирамицин: прошлое и будущее антибиотика с плейотропными эффектами в терапии внебольничных инфекций. Фармация и фармакология. 2024; 12(2): 150-71. [Butranova O.I., Zyryanov S.K., Abramova A.A. Spiramycin: The past and future of an antibiotic with pleiotropic effects in the therapy of community-acquired infections. Pharmacy & Pharmacology. 2024; 12(2): 150-71(in Russian)]. https://dx.doi.org/10.19163/2307-9266-2024-12-2-150-171
- Franco P.S., Gomes A.O., Barbosa B.F., Angeloni M.B., Silva N.M., Teixeira-Carvalho A. et al. Azithromycin and spiramycin induce anti-inflammatory response in human trophoblastic (BeWo) cells infected by toxoplasma gondii but are able to control infection. Placenta. 2011; 32(11): 838-44. https://dx.doi.org/10.1016/j.placenta.2011.08.012
- Montoya J.G., Remington J.S. Management of toxoplasma gondii infection during pregnancy. Clin. Infect. Dis. 2008; 47(4): 554-66. https://dx.doi.org/10.1086/590149
- Dunn D., Wallon M., Peyron F., Petersen E., Peckham C., Gilbert R. Mother-to- child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999; 353(9167): 1829-33. https://dx.doi.org/10.1016/S0140-6736(98)08220-8
- Rabilloud M., Wallon M., Peyron F. In utero and at birth diagnosis of congenital toxoplasmosis: use of likelihood ratios for clinical management. Pediatr. Infect. Dis. J. 2010; 29(5): 421-5. https://dx.doi.org/10.1097/INF.0b013e3181c80493
- Wallon M., Peyron F. Effect of antenatal treatment on the severity of congenital toxoplasmosis. Clin. Infect. Dis. 2016; 62(6): 811-2. https://dx.doi.org/10.1093/cid/civ1035
- Prusa A.R., Kasper D.C., Pollak A., Gleiss A., Waldhoer T., Hayde M. The Austrian toxoplasmosis register, 1992–2008. Clin. Infect. Dis. 2015; 60(2): e4-10. https://dx.doi.org/10.1093/cid/ciu724
- Wei H.X., Wei S.S., Lindsay D.S., Peng H.J. A Systematic review and meta-analysis of the efficacy of anti-toxoplasma gondii medicines in humans. PLOS One. 2015; 10(9): e0138204. https://dx.doi.org/10.1371/journal.pone.0138204
- Kang J.K., Kang H.K., Hyun C.G. Anti-inflammatory effects of spiramycin in LPS-activated RAW 264.7 macrophages. Molecules. 2022; 27(10): 3202. https://dx.doi.org/10.3390/molecules27103202
- Omura S., Sano H., Sunazuka T. Structure activity relationships of spiramycins. J. Antimicrob. Chemother. 1985; 16(Suppl. A): 1-11. https://dx.doi.org/10.1093/jac/16.suppl_a.1
- Moffat A.C., Osselton M.D., Widdop B., eds. Clarke’s analysis of drugs and poisons. Vol. 2. 3rd ed. London, UK: Pharmaceutical Press, 2004. 1248 p.
- Montoya J.G., Laessig K., Fazeli M.S., Siliman G., Yoon S.S., Drake-Shanahan E. et al. A fresh look at the role of spiramycin in preventing a neglected disease: meta-analyses of observational studies. Eur. J. Med. Res. 2021; 26(1): 143. https://dx.doi.org/10.1186/s40001-021-00606-7
- Elazab S.T., Elshater N.S., Hashem Y.H., Al-Atfeehy N.M., Lee E.B.,Park S.C. et al. Pharmacokinetic / Pharmacodynamic modeling of spiramycin against mycoplasma synoviae in chickens. Pathogens. 2021; 10(10): 1238. https://dx.doi.org/10.3390/pathogens10101238
- Zahari N.I.N., Engku Abd Rahman E.N.S., Irekeola A.A., Ahmed N., Rabaan A.A., Alotaibi J. et al. A review of the resistance mechanisms for β-lactams, macrolides and fluoroquinolones among streptococcus pneumoniae. Medicina (Kaunas). 2023; 59(11): 1927. https://dx.doi.org/10.3390/medicina59111927
- Громова О.А., Торшин И.Ю. Хемоинформационное исследование спирамицина в сравнении с другими антибиотиками. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2025; 18(1): 80-94. [Gromovа O.A., Torshin I.Yu. Chemoinformatic study of spiramycin in comparison with other antibiotics. Farmakoekonomika. Modern pharmacoeconomics and pharmacoepidemiology. 2025; 18(1): 80-94 (in Russian). https://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2025.296
- Cornelisse V.J., Sherman C.J., Hocking J.S., Williams H., Zhang L.,Chen M.Y. et al. Concordance of chlamydia infections of the rectum and urethra in same-sex male partnerships: a cross-sectional analysis. BMC Infect. Dis. 2017; 17(1): 22. https://dx.doi.org/10.1186/s12879-016-2141-7
- Тютюнник В.Л., Михайлова О.И., Кан Н.Е., Мирзабекова Д.Д. Современные представления терапии урогенитального хламидиоза при беременности. Акушерство и гинекология. 2024; 4: 148-54. [Tyutyunnik V.L., Mikhailova O.I., Kan N.E., Mirzabekova D.D. Modern concepts of therapy of urogenital chlamydia in pregnancy. Obstetrics and Gynecology. 2024; (4): 148-54 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.64
- Doernberg S.B., Komarow L., Tran T.T.T., Sund Z., Pandori M.W., Jensen D. et al. Simultaneous evaluation of diagnostic assays for pharyngeal and rectal neisseria gonorrhoeae and chlamydia trachomatis using a master protocol. Clin. Infect. Dis. 2020; 71(9): 2314-22. https://dx.doi.org/10.1093/cid/ciz1105
- CDC. Chlamydial Infections. Chlamydial infection among adolescents and adults. Available at: https://www.cdc.gov/std/treatment-guidelines/chlamydia.htm#print
- Workowski K.A., Bachmann L.H., Chan P.A., Johnston C.M., Johnston C., Muzny C.A. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm. Rep. 2021; 70(4): 1-187. https://dx.doi.org/10.15585/mmwr.rr7004a1
- Ковалёва И.В. Клинические рекомендации по антибактериальной терапии внебольничных инфекций: на что обратить внимание практическому врачу? Лечащий Врач. 2025; 5(29): 59-64. [Kovaleva I.V.Clinical recommendations for antibacterial therapy of community-acquired infections: what should a practitioner pay attention to? Lechaschi Vrach. 2025; 5(29): 59-64 (in Russian)]. https://orcid.org/0000-0003-0171-4374
- Довлетханова Э.Р., Абакарова П.Р. Антибактериальная терапия при воспалительных заболеваниях органов малого таза: современные тенденции. Акушерство и гинекология. 2024; 12: 176-84. [Dovletkhanova E.R., Abakarova P.R. Antibacterial therapy in pelvic inflammatory diseases: current trends. Obstetrics and Gynecology. 2024; (12): 176-84 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.285
Received 25.08.2025
Accepted 01.10.2025
About the Authors
Inna A. Apolikhina, Honored Doctor of the Russian Federation, Dr. Med. Sci., Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation, Professor at the Department of Obstetrics and Gynecology, Department of Vocational Education, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, 117997, Russia, Moscow,Ac. Oparina str., 4; Professor at the Department of Obstetrics, Gynecology, Perinatology and Reproductology, I.M. Sechenov First MSMU, Ministry of Health of Russia (Sechenov University); President of the Association of Aesthetic Gynecology Specialists, apolikhina@inbox.ru, https://orcid.org/0000-0002-4581-6295
Zhasmina Zh. Suleimanova, оbstetrician-gynecologist, Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, 117997, Russia, Moscow, Ak. Oparina str., 4, +7(916)028-55-33, zhasmin020@mail.ru, https://orcid.org/0000-0003-1232-5753
Tatiana A. Teterina, PhD, obstetrician-gynecologist, USD, Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, 117997, Russia, Moscow, Ak. Oparina str., 4, Expert of the Association of Aesthetic Gynecology Specialists (ASEG), palpebra@inbox.ru,
https://orcid.org/0000-0003-0990-2302
Corresponding author: Zhasmina Zh. Suleimanova, zhasmin020@mail.ru
Similar Articles
